A practical reference on bremelanotide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-22 and is reviewed periodically as new material appears.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
Lyophilized peptide material is generally stored at -20 °C or below to limit degradation, while reconstituted solutions are less stable and are typically kept refrigerated and protected from light. Repeated freeze-thaw cycles can accelerate aggregation and should be minimized. Stability for any specific lot depends on purity, moisture content, and packaging. Handling in a temperature-controlled environment reduces variability across replicates, and exposure to ambient humidity during weighing can introduce error. Aliquotting reduces the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.
Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-MSH |
| Molecular mass | Approximately 1025 Da | Peptide-scale molecule |
| Route | Subcutaneous injection | Intranasal form used in early research |
| Common synonyms | PT-141; bremelanotide acetate | Research code and salt form |
| Typical storage | 2-8 °C, protected from light | Unopened vial condition |
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
When the news of the curative properties of penicillin broke, Fleming revelled in the publicity. Journalists told a familiar story of a lone British scientist and a serendipitous discovery. The British medical historian Bill Bynum wrote:The discovery and development of penicillin is an object lesson of modernity: the contrast between an alert individual (Fleming) making an isolated observation and the exploitation of the observation through teamwork and the scientific division of labour (Florey and his group). The discovery was old science, but the drug itself required new ways of doing science. In 1943, the Nobel committee received a single nomination for the Nobel Prize in Physiology or Medicine for Fleming and Florey from the British biochemist Rudolph Peters. The secretary of the Nobel committee, Göran Liljestrand, made an assessment of Fleming and Florey in the same year, but little was known about penicillin in Sweden at the time, and he concluded that more information was required. The following year, there was one nomination for Fleming alone and one for Fleming, Florey and Chain. Liljestrand and Nanna Svartz considered their work, and while both judged Fleming and Florey equally worthy of a Nobel Prize, the Nobel committee was divided, and decided to award the prize that year to Joseph Erlanger and Herbert S. Gasser instead. In 1945 there were a large number of nominations for Florey and Fleming or both, and one for Chain, from Liljestrand, who nominated all three.
==== Predictive Low Glucose Suspend (PLGS) ==== A step forward from threshold suspend systems, predictive low glucose suspend (PLGS) systems use a mathematical model to extrapolate predicted future blood sugar levels based on recent past readings from a CGM. This allows the system to reduce or halt insulin delivery prior to a predicted hypoglycemic event.
=== Phase 2 === Abatacept (Orencia) – injection – alopecia areata – T cell activation inhibitor Amlitelimab (KY-1005, SAR-445229) – subcutaneous injection – alopecia areata – OX40 ligand inhibitor BAY-1158061 (HMI-115) – subcutaneous injection – alopecia – prolactin receptor monoclonal antibody (prolactin receptor inhibitor) Bempikibart (ADX-914, BMS-986265) – subcutaneous injection – alopecia areata – CRLF2 protein antagonist, interleukin 7 receptor α subunit inhibitor Bimatoprost (Lumigan) – topical – alopecia – prostaglandin F receptor agonist (prostaglandin F2α analogue) Botulinum toxin A (Xeomin; incobotulinum toxin A) – intradermal – alopecia – acetylcholine release inhibitor and neuromuscular blocking agent CKD-498 – oral – alopecia – undefined mechanism of action Daxdilimab (HZN-7734; MEDI-7734; VIB-7734) – oral – alopecia areata – anti-ILT7 human monoclonal antibody/dendritic cell inhibitor Delgocitinib (Anzupgo, Corectim; JTE-052, LEO-124249, LP-0133) – unknown – alopecia areata – Janus kinase inhibitor Deucravacitinib (Sotyktu; BMS-986165) – oral – alopecia areata – TYK2 kinase inhibitor Finasteride/latanoprost/minoxidil (TH-07; Triple Hair) – topical – alopecia – combination drug/multiple mechanisms of action FOL-005 (osteopontin-derived peptide) – intradermal – alopecia – undefined mechanism of action GT-20029 (AR-PROTAC) – topical – alopecia – androgen receptor degradation enhancer KL-130008 – oral – alopecia areata – Janus kinase inhibitor Latanoprost (DLQ01; DLQ-01) – topical – androgenic alopecia – prostaglandin F receptor agonist (prostaglandin F2α analogue) NXC-736 – oral – alopecia areata – sphingosine 1 phosphate receptor antagonist Rezpegaldesleukin (Rezpeg; LY-3471851, NKTR-358) – unknown – alopecia areata – interleukin-2 conjugate/modulator RK-023 (nobiprostolan) – topical – alopecia, hypotrichosis – undefined mechanism of action (prostaglandin F2α analogue) Rosnilimab (ANB-030) – subcutaneous injection – alopecia areata – programmed cell death 1 receptor agonist Ruxolitinib (Jakafi, Jakavi, Opzelura; INCB-018424) – topical – alopecia areata – Janus kinase 1 inhibitor, Janus kinase 2 inhibitor SIS-302-AA – unspecified – alopecia areata – undefined mechanism of action Suvomipic (PP405; PP-405; JXL069; JXL-069) – topical – alopecia – mitochondrial pyruvate carrier (MPC) inhibitor SYHX-1901 – oral – alopecia areata – Janus kinase inhibitor, Syk kinase inhibitor TDM-105795 (CU-40101) – topical – alopecia – thyroid hormone receptor agonist
Sources: en.wikipedia.org
=== State of Federal Germany === After World War II, the Prussian province of Schleswig-Holstein came under British occupation. On 23 August 1946, the military government abolished the province and reconstituted it as a separate Land. On 9 September 1946, the British and Soviets offered Denmark South Schleswig, in the Septembernote. In this note, they gave Denmark carte blanche on how to deal with the German-speaking South Schleswigers, whether to integrate them into the Danish state or to forcibly expel them from South Schleswig, as was being done to Germans in Eastern Europe. Denmark's then Prime Minister, the Liberal Party's Knud Kristensen, enthusiastically accepted the offer of South Schleswig reunification with Denmark. A survey showed that 75% of the Danish population supported the incorporation, 500,000 signatures had been collected in support of it, and the Danish South Schleswig Association had sent the government a formal request for incorporation. However, the dominating Social Liberal Party feared that Denmark might again face destructive wars like the two Schleswig Wars once Germany recovered from World War II. Given that the Germans had conquered Denmark in six hours during the German invasion of Denmark, they believed Denmark would not stand a chance in such a scenario. Therefore, they pressured the Prime Minister to call for new elections, where the Liberal Party did not secure enough votes to form a government.
=== Other organizations and programs === HOL LiNK program (Literacy and Numeracy Knowledge), by Hands On Learning Australia Liberty in North Korea (LiNK), a refugee resettling group Link Campus University, Rome, Italy LINKS units, later student volunteering units, of St John Ambulance in England and Wales Local involvement networks (LINks), National Health Service England Project LINK, a UN project to build global macroeconomic models The Link (UK organization) for "Anglo-German friendship", UK pro-Nazi organization, 1937–1939 The Links, a social and service organization of American Black women
== Biosynthesis == Elabela gene encodes a pre-proprotein of 54 amino acids, with a signal peptide in the N-terminal region. After translocation into the endoplasmic reticulum and cleavage of the signal peptide, the proprotein of 32 amino acids may generate several active fragments.
It has to be appreciated that at the time the menace of doping for the health of athletes or of the purity of competition had yet to enter the morals because, after this marathon, the official race report said: The marathon has shown from a medical point of view how drugs can be very useful to athletes in long-distance races. Hicks was, in the phrase of the time, "between life and death" but recovered, collected his gold medal a few days later, and lived until 1952. Nonetheless, he never again took part in athletics.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide that activates melanocortin receptors. It is given by injection and was approved in the United States in 2019 for a specific low-desire diagnosis in premenopausal women. It is not a hormonal therapy.
Earlier approaches were largely hormonal or psychological in focus, whereas this compound acts on central melanocortin signalling. It is not a vasodilator and does not share the mechanism of phosphodiesterase inhibitors. Head-to-head comparative data are limited.
Placebo responses in desire trials are large, so the average drug-placebo separation is small. Reporting therefore relies on validated questionnaires with statistical ranges. Individual responses vary widely.
Storage at -20 °C or below is standard for long-term stability. Desiccant and sealed containers limit moisture exposure. Solutions are prepared only when needed.